Prospective study of platelet derived growth factor in wound healing of diabetic foot ulcers in Indian population

Purushothaman Rangaswamy; Shaikh Afzal Rubby; Kanniga Prasanth

doi:10.18203/2349-2902.isj20164428

Authors

Purushothaman Rangaswamy Department of General Surgery, ESIC Medical College and Hospital, Coimbatore, Tamil Nadu, India
Shaikh Afzal Rubby Department of General Surgery, ESIC Medical College and Hospital, Coimbatore, Tamil Nadu, India
Kanniga Prasanth Department of General Surgery, ESIC Medical College and Hospital, Coimbatore, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2349-2902.isj20164428

Keywords:

Diabetic foot ulcer, PDGF, Ulcers, Wound healing

Abstract

Background: Recently the world health organization reported a global prevalence of diabetes exceeding 300 million people, predicting a further 60-70% increase by the year 2030, which means India alone will have 100 million people by the year 2030.Wound healing is problematic in diabetic patients. Encouraging results have shown that PDGF application is better than good wound care alone. But the evidence to demonstrate the safety and efficacy of PDGF in diabetic ulcer is scanty.

Methods: The present study was carried out at PSG Hospitals, Coimbatore, Tamil Nadu, India for a period of one year, where 50 patients with diabetic foot ulcers were included in the present study. Prospective randomized controlled trail was designed for the study. 50 patients with diabetic foot ulcers admitted in surgery wards at PSG Hospitals over a period from August 2011 to August 2012. 25 patients were in the study/treatment group, 25 patients were in the control group.

Results: Out of 50, patients, 25 took treatment in the form of conventional normal saline dressings and 25 took treatment with rh - PDGF dressing once a day. Glycaemic control and adequate control of infection was maintained in both the groups. X-ray foot was taken for all patients and bony involvement was excluded. The initial area measurement was taken on day 01 and final area measurement on day 15 was taken on transparent sheet. Plannimetry was used to measure the outcome that is the target ulcer area using a transparent graph sheet. Results were calculated by using student ‘t’ test.

Conclusions: The wounds in the study group treated with rh-PDGF dressing contracted more than the wounds in the control group (38.55% Vs 12.79%; P≤ 0.001- statistically significant) which indicates rh-PDGF dressing is an effective modality to facilitate wound contraction in patients suffering from diabetes. Rh-PDGF dressing is found to be more effective, safe promoter of wound healing and can be used as an adjunct to saline dressing for healing of diabetic wounds and healing of ulcers receiving PDGF was significantly faster as compared to ulcers receiving placebo.

Metrics

Metrics Loading ...

References

The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-97.

Reiber GE, Ledous WE. Epidemiology of diabetic foot ulcers and amputations: evidence for prevention. In Williams R, Herman W, Kinmonth A. The evidence base for diabetes care. London : John Wileyand Sons; 2002:641.665

Heldin CH. Structural and functional studies on platelet-derived growth factor. EMBO J. 1992;11(12):4251-9.

Shrivastava SR, Shrivastava SP, Ramasamy. Role of self-care in management of diabetes mellitus. Journal Diabetes Metabolic. 2013;12:14

Holliday E. Hints of unique genetic effects for type 2 diabetes in India. Diabetes. 2013;62(5):1369-70.

David JM, Jonathon J, Jill S, Brian IS, Jesse AB. Effectiveness of platelet release rate for the treatment of diabetic neuropathic foot ulcer. Diabetes Care. 2001;24:483-88.

David JM, Jonathan K, Jesse BA. Healing of diabetic neuropathic foot foot ulcers receiving standard treatment. Diabetes Care. 1999;22:692-5.

Ravari H, Modaghegh MH, Kazemzadeh GH, Johari HG, Vatachi AM. Sangaki A, et al. Comparison of vaccum assiated closure and moist dressing in the treatment of diabetic foot ulcers. J Cutaneous Aesthetic Surg. 2013;6(1):17-20.

Zhang J, Hu ZC, Chen D, Guo D, Zhu JY, Tang B. Effectiveness and safety of negative pressure wound therapy for diabetic foot ulcers: a meta-analysis. Plastic Reconstructive Surg. 2014;134(1):141-51.

Polka A, Franek A, Taradaj J. High-voltage pulsed current electrical stimulation in wound treatment. Advances Wound Care. 2014;3(2):104-17.

Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, Brink A, Koelmay MJ. Hyperbaric oxygen for the treatment of diabetic foot ulcers: A systematic review. European J Vascular Endovascular Surg. 2014;47(6):647-55.

Rio T, Green J, Kirsner RS. Vascular endothelial growth factor delivery via gene therapy for diabetic wounds: first steps. J Investigative Dermatol. 2009;129(9):2084.

Single S, Singla S, Kumar A, Siggla M. Role of epidermal growth factor in healing of diabetic foot ulcers. Indian J Surg. 2012;74(6):451-5.

Muha J. Local wound care in diabetic foot complications aggressive risk management and ulcer treatment to avoid amputation. Post Graduate Medicine. 1999;106(1):97-102.

Shulman T, Sauer FG, Jackman RM, Change CN, Landofi NF. An antibody reactive with domain 4 of the platelet derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerizarization. J Boil Chem. 1997;272(28):17400-4.

Edmonds M. The diabetic foot. Diabetes Metab Res Rew. 2004;20(1):9-12.

Margolis DJ, Storm BL, Kantor J, Berlin JA, Satanna J. Effectiveness of platelet release rate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001;24:483-8.

Hardikar JV, Reddy C, Bung DD, Varma N, Prakash PS, Prasad ED, et al. Efficacy of recombinant human platelet derived growth factor (rh PDGF) based gel in diabetic foot ulcer, a randomized, multicenter, double-blind, placebo- controlled study in India. Wounds. 2005;17(6):141-52.

Ogebra AO, Adedokun A, Fasanmade OA, Ajani M. The foot at risk in Nigerians with diabetes mellitus. Int J Endocrinol Metab. 2005;4:165-73.

Boyko EJ, Ahroni JH, Stensei V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic ulcer. The Seattle Diabetic Foot Study. Diabetes Care. 1999;22:1036-42.

Mam MK, Dhar KL, Pawar I. Some observations on diabetic foot. Indian J Orthopaedics. 1998;33:197-9.

Wieman TJ, Smilell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor- bb (becaplermin) in patients with chronic neuropathic diabetic ulcers a phase 3 randomized placebo-controlled double blind study. Diabetes Care. 1998;5:822-7.

Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standarad treatment. a meta-analysis. Diabetes Care. 1999;22(5)692-5.

Embill JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B. Becaplermin for healing chronic lower extremity diabetic ulcer; an open lable clinical evaluation of efficacy. Wound Repair Regeneration. 2000;8(3):162-8.

Nagai MK, John ME. Becaplermin; recombinant platelets derived growth factor, a new treatment of healing diabetic foot ulcers expert opinion. Biological Therapy. 2002;2(2):211-8.

Lone AM, Zaroo MI, Laway BA, Bashir SA, Rasool A. Vacuum assisted closure versus conventional dressing in the management of diabetic foot ulcer: a prospective case control study. Diabetic Foot Ankle. 2014;5:10.